文献速递脊柱关节炎

血清蛋白质组学数据分析发现银屑病关节炎中基线β-防御素2与IL-17阻断临床应答存在定量关联

Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis.
PubMed 文献 · RMD Open · 2023-01-01

研究分析近2000例银屑病关节炎(PsA)患者血清蛋白质组学数据,发现基线β-防御素2(BD-2)水平与司库奇尤单抗(而非安慰剂)的临床应答稳健相关,并在两项独立研究中验证;BD-2亦可预测阿达木单抗应答,但在类风湿关节炎中不能预测司库奇尤单抗应答。

要点

  • 基线BD-2水平与PsA患者对司库奇尤单抗的ACR20/50/70应答稳健相关,与安慰剂无关。
  • BD-2的预测性独立于基线PASI,且在用药后4周即可观察到、维持至52周。
  • BD-2亦可预测阿达木单抗应答,但在类风湿关节炎中不能预测司库奇尤单抗应答。

核心结论

  • 在PsA中,基线BD-2与司库奇尤单抗临床应答存在定量关联;基线BD-2水平高的患者治疗后达到并维持更高的临床应答率。

研究设计与样本

  • 分析近2000例PsA患者(来自司库奇尤单抗安慰剂对照III期临床试验)的血清蛋白质组学数据,采用统计学习与受控特征选择发现预测性生物标志物。
  • 顶级候选标志物用ELISA验证,并在另一项近800例PsA患者(接受司库奇尤单抗或阿达木单抗治疗)的试验中单独评估。

主要发现

  • 基线血清BD-2水平与后续司库奇尤单抗临床应答(如ACR20、ACR50、ACR70)稳健相关,但与安慰剂无关。
  • 该发现在两项未用于发现的独立临床研究中得到验证。
  • BD-2的预测性独立于基线PASI;BD-2与司库奇尤单抗应答的关联最早在4周观察到,并维持至52周。
  • BD-2亦可预测阿达木单抗治疗应答;与PsA不同,BD-2在类风湿关节炎中不能预测司库奇尤单抗应答。

关键数值与推荐

  • 基线BD-2水平与司库奇尤单抗的ACR20、ACR50、ACR70应答相关,但与安慰剂无关。
  • BD-2与司库奇尤单抗应答的关联最早在4周观察到,维持至52周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking. METHODS: We analysed proteomics data from serum samples of nearly 2000 patients with PsA in placebo-controlled phase-III clinical trials of the interleukin-17 inhibitor secukinumab. To discover predictive biomarkers of clinical response, we used statistical learning with controlled feature selection. The top candidate was validated using an ELISA and was separately assessed in a trial of almost 800 patients with PsA treated with secukinumab or the tumour necrosis factor inhibitor adalimumab. RESULTS: Serum levels of beta-defensin 2 (BD-2) at baseline were found to be robustly associated with subsequent clinical response (eg, American College of Rheumatology definition of 20%, 50% and 70% improvement) to secukinumab, but not to placebo. This finding was validated in two independent clinical studies not used for discovery. Although BD-2 is known to be associated with psoriasis severity, the predictivity of BD-2 was independent of baseline Psoriasis Area and Severity Index. The association between BD-2 and response to secukinumab was observed as early as 4 weeks and maintained up to 52 weeks. BD-2 was also found to predict response to treatment with adalimumab. Unlike in PsA, BD-2 was not predictive of response to secukinumab in rheumatoid arthritis. CONCLUSIONS: In PsA, BD-2 at baseline is quantitatively associated with clinical response to secukinumab. Patients with high levels of BD-2 at baseline reach and sustain higher rates of clinical response after treatment with secukinumab.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Cardner M, Tuckwell D, Kostikova A, et al. Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis. RMD Open. 2023. PMID: 37321668. doi:10.1136/rmdopen-2023-003042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。